EP1416965B8 - Assay method for alzheimer's disease - Google Patents

Assay method for alzheimer's disease Download PDF

Info

Publication number
EP1416965B8
EP1416965B8 EP02766022A EP02766022A EP1416965B8 EP 1416965 B8 EP1416965 B8 EP 1416965B8 EP 02766022 A EP02766022 A EP 02766022A EP 02766022 A EP02766022 A EP 02766022A EP 1416965 B8 EP1416965 B8 EP 1416965B8
Authority
EP
European Patent Office
Prior art keywords
disease
alzheimer
beta
assay method
preclinical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02766022A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1416965B1 (en
EP1416965A4 (en
EP1416965A2 (en
Inventor
David M. Holtzman
Ronald Demattos
Kelly R. Bales
David J. Cummins
Steven M. Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Eli Lilly and Co
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Eli Lilly and Co
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Eli Lilly and Co, Washington University in St Louis WUSTL filed Critical University of Washington
Priority to EP07024341A priority Critical patent/EP1944040B1/en
Priority to DK07024341.5T priority patent/DK1944040T3/da
Publication of EP1416965A2 publication Critical patent/EP1416965A2/en
Publication of EP1416965A4 publication Critical patent/EP1416965A4/en
Publication of EP1416965B1 publication Critical patent/EP1416965B1/en
Application granted granted Critical
Publication of EP1416965B8 publication Critical patent/EP1416965B8/en
Priority to CY20081100267T priority patent/CY1107901T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02766022A 2001-08-17 2002-08-16 Assay method for alzheimer's disease Expired - Lifetime EP1416965B8 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07024341A EP1944040B1 (en) 2001-08-17 2002-08-16 Assay method for Alzheimer's disease
DK07024341.5T DK1944040T3 (da) 2001-08-17 2002-08-16 Analysefremgangsmåde for Alzheimers sygdom
CY20081100267T CY1107901T1 (el) 2001-08-17 2008-03-07 Μεθοδος προσδιορισμου για ασθενεια alzheimer

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31322101P 2001-08-17 2001-08-17
US31322401P 2001-08-17 2001-08-17
US313221P 2001-08-17
US313224P 2001-08-17
US33498701P 2001-10-23 2001-10-23
US334987P 2001-10-23
PCT/US2002/026321 WO2003015617A2 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07024341A Division EP1944040B1 (en) 2001-08-17 2002-08-16 Assay method for Alzheimer's disease

Publications (4)

Publication Number Publication Date
EP1416965A2 EP1416965A2 (en) 2004-05-12
EP1416965A4 EP1416965A4 (en) 2005-11-02
EP1416965B1 EP1416965B1 (en) 2007-12-19
EP1416965B8 true EP1416965B8 (en) 2008-02-13

Family

ID=27405654

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02766022A Expired - Lifetime EP1416965B8 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Country Status (10)

Country Link
EP (1) EP1416965B8 (enExample)
JP (2) JP4511830B2 (enExample)
AT (1) ATE381346T1 (enExample)
CA (1) CA2457145C (enExample)
CY (1) CY1107901T1 (enExample)
DE (1) DE60224200T2 (enExample)
DK (1) DK1416965T3 (enExample)
ES (1) ES2295401T3 (enExample)
PT (1) PT1416965E (enExample)
WO (1) WO2003015617A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
US7771722B2 (en) 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7575747B2 (en) 2003-02-10 2009-08-18 Applied Molecular Evolution Aβ binding molecules
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2675847C (en) 2007-01-18 2014-12-30 Eli Lilly And Company Pegylated a.beta. fab
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2010093001A1 (ja) * 2009-02-13 2010-08-19 国立大学法人大阪大学 アルツハイマー病の診断方法および診断薬
KR101531949B1 (ko) 2009-12-11 2015-06-26 아라클론 바이오테크, 에스.엘. 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
KR102496845B1 (ko) * 2018-08-08 2023-02-08 서울대학교산학협력단 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298436B1 (en) * 1992-10-26 2010-07-14 Elan Pharmaceuticals, Inc. Methods for the identification of Beta-amyloid peptide (BAP) release inhibitor compounds
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
IL151378A0 (en) * 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide

Also Published As

Publication number Publication date
EP1416965B1 (en) 2007-12-19
JP2004538477A (ja) 2004-12-24
CA2457145A1 (en) 2003-02-27
EP1416965A4 (en) 2005-11-02
PT1416965E (pt) 2008-04-01
ATE381346T1 (de) 2008-01-15
CA2457145C (en) 2010-12-21
ES2295401T3 (es) 2008-04-16
JP2010044078A (ja) 2010-02-25
EP1416965A2 (en) 2004-05-12
DE60224200D1 (de) 2008-01-31
DK1416965T3 (da) 2008-05-05
HK1061960A1 (en) 2004-10-15
WO2003015617A3 (en) 2004-01-29
DE60224200T2 (de) 2008-07-10
JP5162553B2 (ja) 2013-03-13
WO2003015617A2 (en) 2003-02-27
CY1107901T1 (el) 2013-09-04
JP4511830B2 (ja) 2010-07-28

Similar Documents

Publication Publication Date Title
CY1107901T1 (el) Μεθοδος προσδιορισμου για ασθενεια alzheimer
EP1944040A3 (en) Assay method for Alzheimer's disease
WO2002067760A3 (en) Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
CA2212058A1 (en) Preparation and use of a specific gaba-a.alpha.5 receptor ligand for treatment of alzheimer's disease
CA2221160A1 (en) Automated infusion system with dose rate calculator
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
WO2000048647A3 (en) Apparatus for the dialysis of blood, method for fabricating the same, and method for the dialysis of blood
WO1997011667A3 (en) Therapeutic applications using horse serum
AUPO943297A0 (en) Diagnostic test for alzheimer's disease
AU2001263943A1 (en) Method for detecting alpha-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient
GR3034035T3 (en) A process for the preparation of factor ix from biological sources
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
AU2002211577A1 (en) Protecting therapeutic compositions from host-mediated inactivation
WO2002074322A3 (en) Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2002366555A1 (en) Diagnostic for early stage alzheimer's disease
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
AU2003208857A1 (en) Diagnostic and therapeutic use of caps
WO2002018633A3 (en) Determination of the ability of patients to respond to tumour treatment
UA10262A (uk) Спосіб ультразвукової діагностики стану судин головного мозку

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040217

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1061960

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20050921

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

RIN2 Information on inventor provided after grant (corrected)

Inventor name: DEMATTOS, RONALD

Inventor name: BALES, KELLY, R.

Inventor name: HOLTZMAN, DAVID, M.

Inventor name: CUMMINS, DAVID, J.

Inventor name: PAUL, STEVEN, M.

REF Corresponds to:

Ref document number: 60224200

Country of ref document: DE

Date of ref document: 20080131

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20080400343

Country of ref document: GR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE S.A.

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20080319

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2295401

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E001942

Country of ref document: EE

Effective date: 20080314

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1061960

Country of ref document: HK

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080922

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120816

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20131001

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20190619

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20190729

Year of fee payment: 18

Ref country code: IE

Payment date: 20190726

Year of fee payment: 18

Ref country code: CZ

Payment date: 20190726

Year of fee payment: 18

Ref country code: DK

Payment date: 20190726

Year of fee payment: 18

Ref country code: EE

Payment date: 20190731

Year of fee payment: 18

Ref country code: SE

Payment date: 20190808

Year of fee payment: 18

Ref country code: FI

Payment date: 20190726

Year of fee payment: 18

Ref country code: MC

Payment date: 20190729

Year of fee payment: 18

Ref country code: SK

Payment date: 20190725

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20190710

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20190726

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20190808

Year of fee payment: 18

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E001942

Country of ref document: EE

Effective date: 20200831

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20200831

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 381346

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200816

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 3212

Country of ref document: SK

Effective date: 20200816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200816

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200816

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200816

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210317

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200816

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200816

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20210720

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20210720

Year of fee payment: 20

Ref country code: FR

Payment date: 20210722

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20210722

Year of fee payment: 20

Ref country code: TR

Payment date: 20210730

Year of fee payment: 20

Ref country code: DE

Payment date: 20210720

Year of fee payment: 20

Ref country code: BE

Payment date: 20210720

Year of fee payment: 20

Ref country code: CH

Payment date: 20210722

Year of fee payment: 20

Ref country code: ES

Payment date: 20210901

Year of fee payment: 20

Ref country code: GB

Payment date: 20210720

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60224200

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20220815

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220830

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20220815

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20220816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220815

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220817